BPMUF News Alert Basilea Pharmaceutic (BPMUF) 105.0000 09/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Basilea Pharmaceutic (BPMUF) 105.0000 $BPMUF

Basilea's partner Astellas receives notification from U.S. FDA of acceptance of filing of isavuconazole NDA for the treatment of invasive aspergillosis and invasive mucormycosis
GlobeNewswire - Sat Sep 06, 7:22AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application for isavuconazole submitted by Basilea's license partner Astellas Pharma Inc. The NDA seeks approval of isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis) in adults. In accordance with the FDA Prescription Drug User Fee Act (PDUFA), the FDA designated the date of March 8, 2015 for the completion of the review.

Extensive data presented on Basilea's anti-infectives isavuconazole, ceftobiprole and BAL30072 at ICAAC
GlobeNewswire - Fri Sep 05, 12:19AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) announces today that extensive data will be presented on the anti-fungal isavuconazole and the antibiotics ceftobiprole and BAL30072 at the 54 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, 2014 in Washington, DC (USA).

European Medicines Agency accepts Basilea's isavuconazole Marketing Authorization Application for review
GlobeNewswire - Thu Aug 21, 12:20AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) announces today that the European Medicines Agency (EMA) has accepted its isavuconazole Marketing Authorization Application (MAA) for review. Basilea's MAA seeks approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis (zygomycosis) in adults.

Basilea appoints Chief Commercial Officer
GlobeNewswire - Mon Aug 18, 12:21AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that it has appointed David Veitch as Chief Commercial Officer of Basilea Pharmaceutica International Ltd. Mr Veitch will join the company on September 1, 2014. As a member of the management committee, he will be responsible for leading Basilea's commercial operations, including sales, marketing, pricing and market access, reporting to Chief Executive Officer Ronald Scott.

Basilea reports 2014 half-year financials - ceftobiprole launch in Germany planned for second half of 2014
Thomson Reuters ONE - Thu Aug 14, 12:16AM CDT
Basilea Pharmaceutica AG / Basilea reports 2014 half-year financials - ceftobiprole launch in Germany planned for second half of 2014 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Dotmatics Announce Speaker Line-up for User Group Meeting 2014
PR Newswire Europe - Wed Jul 23, 8:59AM CDT
BISHOPS STORTFORD, England, July 23, 2014 /PRNewswire/ --

Basilea to introduce the antibiotic ceftobiprole medocaril in Europe through Quintiles
M2 - Mon Jul 21, 7:59AM CDT
Pharmaceutical products company Basilea Pharmaceutica (Munich K5.MU) Monday announced an agreement for the commercialisation of Zevtera/Mabelio (ceftobiprole medocaril) in Europe through Quintiles (NYSE:Q).

Basilea to launch Zevtera(r)/Mabelio(r) (ceftobiprole medocaril) in Europe through a commercial services provider
GlobeNewswire - Mon Jul 21, 12:23AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) reports that it has entered into an agreement with Quintiles (NYSE: Q) for the commercialization of Zevtera(R)/Mabelio(R) (ceftobiprole medocaril) in Europe.

Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections
Thomson Reuters ONE - Thu Jul 17, 1:46AM CDT
Basilea Pharmaceutica AG / Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Basilea reports that isavuconazole received QIDP designation from U.S. FDA for the treatment of invasive candidiasis
Thomson Reuters ONE - Thu Jul 17, 1:45AM CDT
Basilea Pharmaceutica AG / Basilea reports that isavuconazole received QIDP designation from U.S. FDA for the treatment of invasive candidiasis . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Basilea reports that isavuconazole receives orphan drug designations in Europe for the treatment of invasive mold infections
GlobeNewswire - Mon Jul 14, 2:14AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that the European Commission granted isavuconazole orphan drug designations for the treatment of invasive aspergillosis and mucormycosis (zygomycosis). Isavuconazole is an investigational intravenous and oral broad-spectrum antifungal.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 118

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
SHEIN's EU Training Push Targets Seller Compliance Gaps

Updated Category News Views 102

Chemicals buried in a cheap handbag or kids' accessory can wreck a marketplace's credibility faster than any glossy campaign can repair it. That is the uncomfortable backdrop to SHEIN and SPEAC's November 19 session on EU chemical-safety rules for marketplace sellers. This was not a fashion trend webinar; it was a practical warning about high-risk substances, regulatory...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 99

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight

Updated Category News Views 87

Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...

Continue Reading
Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 66

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 28

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Fire-Resistant Lubricants Offer a Quiet Value Shift

Updated Category News Views 67

Hydraulic fluid is not the sort of product that gets anyone pounding the table, and that is precisely why this little industrial pocket deserves a hard look. The fire-resistant lubricants market is estimated at $2.35 billion in 2026 and projected to reach $2.83 billion by 2031, implying a 3.74% compound annual growth rate. That is not a rocket ship. It is a slow-moving,...

Continue Reading

Top 5 Most Recently Viewed Articles

Roadzen Inc. Executes Strategic Offering to Fuel Growth

Updated Category News Views 156

Roadzen Inc. Announces Strategic Pricing of New Offering Roadzen Inc. (Nasdaq: RDZN), a leader in artificial intelligence solutions within the insurance and mobility sectors, has recently made headlines with the announcement of an offering that promises to bolster its growth trajectory. The company revealed that it is offering 2,222,300 ordinary shares at a public price...

Continue Reading
Merger Announcement: Mallinckrodt and Endo Team Up for Growth

Updated Category News Views 267

Strategic Merger Between Mallinckrodt and Endo Inc In a significant development in the pharmaceutical sector, Mallinckrodt plc and Endo Inc have reached an agreement to join forces in a stock and cash transaction. This partnership is poised to create a combined entity valued at approximately $7 billion, dramatically reshaping both companies' trajectories. Details of the...

Continue Reading
Boardroom Salon Expands in Nashville with Franchise Pro

Updated Category News Views 142

Nashville's Grooming Scene Gears Up for Boardroom's Big Play Call it a bold power move if you'd like; Boardroom Salon for Men is taking a swing at strengthening its roots in Nashville. Guy Gonzales, the franchise veteran and maestro behind the chair, is acquiring existing salons in Brentwood and the West End with intentions to splash two more into the Nashville mix within...

Continue Reading
Premise Health's Digital Wellness Center Earns AAAHC Accreditation

Updated Category News Views 90

Premise Health’s Digital Wellness Center hit a milestone back in 2024 by snagging AAAHC accreditation, making it the first of its kind to earn that badge. Now, you gotta wonder what that really means when folks are still reeling from all the healthcare chaos these days. AAAHC Accreditation: Worth the Hype or Just Noise? This AAAHC stamp of approval isn’t just some...

Continue Reading
Embarking on an Epic Journey: From Czechoslovakia to Japan

Updated Category News Views 194

Embarking on an Epic Journey: From Czechoslovakia to Japan Can you imagine setting off on a grand adventure, driving through diverse landscapes with the iconic World Exhibition in Japan as your destination? This is precisely what a remarkable group of adventurers from Czechoslovakia is preparing to do as they embark on the 'ROBOT Prague – Osaka Expedition'. Inception of...

Continue Reading